How should a 19‑year‑old female with a family history of diabetes, normal fasting glucose (88 mg/dL) and HbA1c (5.2 %), but elevated fasting insulin (47.3 µU/mL) be managed?

Insulin Resistance Without Diabetes: Lifestyle Intervention is First-Line

This 19-year-old woman has isolated hyperinsulinemia (fasting insulin 47.3 µU/mL) with normal glucose metabolism (A1C 5.2%, fasting glucose 88 mg/dL), indicating insulin resistance without diabetes—she requires aggressive lifestyle modification focused on weight management and increased physical activity, with metformin as a consideration if obesity is present and lifestyle measures fail to achieve ≥7% weight reduction.

Understanding the Clinical Picture

This patient presents with a metabolic phenotype that precedes overt diabetes: insulin resistance with compensatory hyperinsulinemia. Her pancreatic beta cells are working overtime to maintain normal glucose levels, but this compensation comes at a cost—elevated insulin itself drives further metabolic dysfunction and increases cardiovascular risk 1, 2.

The family history of diabetes is particularly relevant here. Research demonstrates that individuals with a positive family history show greater glycemic progression over time, even when starting from normoglycemia 3. More specifically, young women with family history of diabetes exhibit postprandial hyperinsulinemia and decreased arterial distensibility despite normal glucose and lipid profiles 2. This suggests early vascular insulin resistance may precede glucose dysmetabolism.

Primary Management Strategy

Lifestyle Intervention (Mandatory First-Line)

The foundation of treatment must be intensive lifestyle modification 4:

• Weight reduction target: If overweight/obese, aim for ≥7% body weight loss through caloric restriction
• Physical activity prescription:
  • Aerobic exercise reduces insulin resistance directly
  • Minimum 150 minutes/week moderate-intensity activity
  • Include resistance training to improve muscle insulin sensitivity
• Dietary modification:
  • Reduce high-glycemic carbohydrates
  • Emphasize whole foods, fiber, lean protein
  • Limit saturated fat intake
  • Culturally appropriate, family-centered approach

Critical point: Lifestyle intervention alone often results in only moderate weight reduction with high likelihood of regain 4. This is why pharmacologic intervention should be considered early if obesity is present.

Pharmacologic Considerations

Metformin as First-Line Medication

If this patient has obesity (BMI ≥30 kg/m²) and lifestyle measures do not achieve adequate weight reduction, metformin should be initiated 4, 5:

• Dosing: Start 500 mg daily, titrate to 2,000 mg/day as tolerated
• Mechanism: Decreases hepatic glucose output and enhances insulin sensitivity without direct beta-cell effects 6
• Benefits beyond glucose: May prevent progression to diabetes in high-risk individuals
• Safety profile: Well-tolerated in young adults; contraindicated only with eGFR <30 mL/min/1.73 m²

GLP-1 Receptor Agonists for Obesity

If BMI ≥30 kg/m² (or ≥27 kg/m² with comorbidities) and weight reduction goals are not met with lifestyle plus metformin, GLP-1 receptor agonist therapy should be strongly considered 4:

• Rationale: GLP-1-based medications achieve 15-25% weight reduction and improve cardiovascular outcomes
• Options: Semaglutide or other approved agents
• Dual benefit: Weight reduction directly improves insulin sensitivity while reducing cardiovascular risk

Monitoring Strategy

Short-Term (Every 3 Months)

• Fasting glucose and insulin: Track whether hyperinsulinemia is improving
• A1C: Should remain <5.7%; progression to ≥5.7% indicates prediabetes
• Weight and waist circumference: Objective measures of intervention efficacy
• Blood pressure and lipids: Screen for metabolic syndrome components

Long-Term (Annually)

• Oral glucose tolerance test: Consider if A1C approaches 5.7% to detect impaired glucose tolerance
• Cardiovascular risk assessment: Family history plus insulin resistance increases ASCVD risk
• Liver function: Screen for metabolic dysfunction-associated steatotic liver disease (MASLD)

Critical Pitfalls to Avoid

1. Do not dismiss normal A1C as "no problem": Hyperinsulinemia with normal glucose represents a pre-disease state that warrants intervention 1, 2

2. Do not delay intervention: The window for preventing diabetes progression is now—waiting for glucose elevation means beta-cell function is already declining

3. Do not underestimate family history: This is not just a risk factor; it's a predictor of accelerated glycemic progression requiring more aggressive preventive measures 3

4. Do not ignore cardiovascular risk: Insulin resistance and hyperinsulinemia independently increase cardiovascular disease risk, even without diabetes 2

5. Do not use insulin or sulfonylureas: These would worsen hyperinsulinemia and are contraindicated in this setting

When to Escalate Care

Refer to endocrinology if:

• A1C progresses to ≥5.7% despite intervention
• Development of acanthosis nigricans worsens (suggests severe insulin resistance)
• Suspicion of secondary causes (PCOS, Cushing's syndrome, medication-induced)
• Consideration of more aggressive pharmacotherapy

Special Consideration: Rule Out Secondary Causes

In a young woman with marked hyperinsulinemia, evaluate for:

• Polycystic ovary syndrome (PCOS): Check menstrual history, hirsutism, testosterone
• Medication effects: Certain antipsychotics, glucocorticoids
• Rare causes: If insulin >100 µU/mL or hypoglycemia develops, consider insulinoma 7 or type B insulin resistance 8

The bottom line: This patient's hyperinsulinemia is a metabolic alarm bell that demands action now, not watchful waiting. Intensive lifestyle modification is non-negotiable, with metformin and potentially GLP-1 receptor agonists as pharmacologic allies if obesity is present and lifestyle measures prove insufficient.